

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2620114/publications.pdf Version: 2024-02-01



I RADT ROSE

#	Article	IF	CITATIONS
1	Does health literacy impact technological comfort in cancer patients?. American Journal of Surgery, 2022, 223, 722-728.	1.8	12
2	Ranking NIH Funding of Surgical Departments Based Upon a Modified Index. Journal of Surgical Research, 2022, 270, 335-340.	1.6	0
3	External tamponade of pseudoaneurysm with balloon catheter. Radiology Case Reports, 2022, 17, 537-539.	0.6	0
4	Are We Undertreating Black Patients with Nonfunctional Pancreatic Neuroendocrine Tumors? Critical Analysis of Current Surveillance Guidelines by Race. Journal of the American College of Surgeons, 2022, 234, 599-606.	0.5	6
5	External validation of four Pancreatic Fistula Risk Score models in the Deep South US: Do racial disparities affect pancreatic fistula prediction?. American Journal of Surgery, 2022, 224, 557-561.	1.8	2
6	Does race affect the long-term survival benefit of systemic therapy in pancreatic adenocarcinoma?. American Journal of Surgery, 2022, , .	1.8	0
7	Gamma Secretase Inhibitors in Cancer: A Current Perspective on Clinical Performance. Oncologist, 2021, 26, e608-e621.	3.7	62
8	Notch Signaling in Vascular Endothelial Cells, Angiogenesis, and Tumor Progression: An Update and Prospective. Frontiers in Cell and Developmental Biology, 2021, 9, 642352.	3.7	88
9	Does health insurance protect against risk of financial catastrophe for pancreatic tumor care? A cost-based review of patients undergoing pancreatic resection at an academic institution. American Journal of Surgery, 2021, 222, 139-144.	1.8	0
10	PET Imaging of Neuroendocrine Tumors. Radiologic Clinics of North America, 2021, 59, 789-799.	1.8	7
11	Cdk5 drives formation of heterogeneous pancreatic neuroendocrine tumors. Oncogenesis, 2021, 10, 83.	4.9	10
12	A growth model of neuroendocrine tumor surrogates and the efficacy of a novel somatostatin-receptor–guided antibody-drug conjugate: Perspectives on clinical response?. Surgery, 2020, 167, 197-203.	1.9	4
13	Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data. Frontiers in Oncology, 2020, 10, 1112.	2.8	12
14	Is radical ever too radical?. American Journal of Surgery, 2020, 220, 282-283.	1.8	1
15	Synthetic Makaluvamine Analogs Decrease c-Kit Expression and Are Cytotoxic to Neuroendocrine Tumor Cells. Molecules, 2020, 25, 4940.	3.8	3
16	Biochemical Predictors of Response to Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Frontiers in Oncology, 2020, 10, 620.	2.8	6
17	Sustained Carbohydrate Antigen 19-9 Response to Neoadjuvant Chemotherapy in Borderline Resectable Pancreatic Cancer Predicts Progression and Survival. Oncologist, 2020, 25, 859-866.	3.7	21
18	Management of Gastrointestinal Neuroendocrine Tumors. Clinical Medicine Insights: Endocrinology and Diabetes, 2019, 12, 117955141988405.	1.9	42

J BART ROSE

#	Article	IF	CITATIONS
19	Significance of radiographic splenic vessel involvement in the pancreatic ductal adenocarcinoma of the body and tail of the gland. Journal of Surgical Oncology, 2019, 120, 262-269.	1.7	18
20	Heterogeneity of Vascular Endothelial Cells, De Novo Arteriogenesis and Therapeutic Implications in Pancreatic Neuroendocrine Tumors. Journal of Clinical Medicine, 2019, 8, 1980.	2.4	23
21	The Role of <i>Notch3</i> in Cancer. Oncologist, 2018, 23, 900-911.	3.7	56
22	Poor Reproducibility of Gallbladder Ejection Fraction by Biliary Scintigraphy for Diagnosis of Biliary Dyskinesia. Journal of the American College of Surgeons, 2018, 226, 155-159.	0.5	17
23	Gallbladder Ejection Fraction and Biliary Scintigraphy. Journal of the American College of Surgeons, 2018, 227, 296.	0.5	1
24	Diagnosis and management of biliary injuries. Current Problems in Surgery, 2017, 54, 406-435.	1.1	13
25	Pattern of CA19-9 response to neoadjuvant chemotherapy in locally advanced, borderline resectable pancreatic cancer to predict progression Journal of Clinical Oncology, 2016, 34, 321-321.	1.6	2
26	The Role of Biliary Carcinoembryonic Antigen-Related Cellular Adhesion Molecule 6 (CEACAM6) as a Biomarker in Cholangiocarcinoma. PLoS ONE, 2016, 11, e0150195.	2.5	15
27	Extended Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer Demonstrates Promising Postoperative Outcomes and Survival. Annals of Surgical Oncology, 2014, 21, 1530-1537.	1.5	127
28	Posterior â€~Superior Mesenteric Artery First' Approach for Resection of Locally Advanced Pancreatic Cancer. Annals of Surgical Oncology, 2014, 21, 1927-1928.	1.5	20
29	Intraoperative and Laparoscopic Ultrasound During Pancreatic Surgery. , 2014, , 161-176.		0
30	Use the Duodenum, It's Right There. JAMA Surgery, 2013, 148, 860.	4.3	18
31	Tu1573 A Comparative Analysis of Plastic Versus Metal Endoscopic Biliary Stents in Borderline Resectable Pancreatic Cancer Patients Undergoing Extended Neoadjuvant Chemotherapy. Gastroenterology, 2013, 144, S-1129.	1.3	1
32	Role of biliary CEACAM6 as a biomarker for cholangiocarcinoma Journal of Clinical Oncology, 2013, 31, 177-177.	1.6	0
33	Extended neoadjuvant chemotherapy (CT)Âin borderline resectable pancreas cancer (BRPC): Is preoperative chemoradiationÂ(CRT) essential?. Journal of Clinical Oncology, 2013, 31, 236-236.	1.6	1
34	Extended neoadjuvant chemotherapy (CT) in borderline resectable pancreas cancer (BRPC) Journal of Clinical Oncology, 2013, 31, 4043-4043.	1.6	1
35	Tu2049 Use the Duodenum, It's Already There: A Retrospective Cohort Study Comparing Biliary Reconstruction to the Either the Jejunum or Duodenum. Gastroenterology, 2012, 142, S-1105.	1.3	0
36	Neuropeptide Y Fragments Derived from Neprilysin Processing Are Neuroprotective in a Transgenic Model of Alzheimer's Disease. Journal of Neuroscience, 2009, 29, 1115-1125.	3.6	75

J BART ROSE

#	Article	IF	CITATIONS
37	Human RNase H1 Discriminates between Subtle Variations in the Structure of the Heteroduplex Substrate. Molecular Pharmacology, 2007, 71, 83-91.	2.3	82
38	The Positional Influence of the Helical Geometry of the Heteroduplex Substrate on Human RNase H1 Catalysis. Molecular Pharmacology, 2007, 71, 73-82.	2.3	35
39	Neuroprotective Effects of Regulators of the Glycogen Synthase Kinase-3Â Signaling Pathway in a Transgenic Model of Alzheimer's Disease Are Associated with Reduced Amyloid Precursor Protein Phosphorylation. Journal of Neuroscience, 2007, 27, 1981-1991.	3.6	265
40	Cerebrolysin decreases amyloid-β production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease. Journal of Neuroscience Research, 2006, 83, 1252-1261.	2.9	98
41	A Study of Lidocaine Iontophoresis for Pediatric Venipuncture. Anesthesia and Analgesia, 2002, 94, 867-871.	2.2	44